This podcast discusses the risks of direct-to-consumer drug advertising in the medical industry, particularly in the case of Trulicity, a diabetes drug. It questions the lack of regulation and transparency in these advertisements, and the extent to which such drugs are more effective than healthy lifestyle choices.